217 related articles for article (PubMed ID: 22856549)
41. Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
Silvino AC; Costa GL; Araújo FC; Ascher DB; Pires DE; Fontes CJ; Carvalho LH; Brito CF; Sousa TN
PLoS One; 2016; 11(7):e0160172. PubMed ID: 27467145
[TBL] [Abstract][Full Text] [Related]
42. Putative Contribution of 8-Aminoquinolines to Preventing Recrudescence of Malaria.
Markus MB
Trop Med Infect Dis; 2023 May; 8(5):. PubMed ID: 37235326
[TBL] [Abstract][Full Text] [Related]
43. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
[TBL] [Abstract][Full Text] [Related]
44. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
45. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Peters W; Stewart LB; Robinson BL
Ann Trop Med Parasitol; 2003 Apr; 97(3):221-36. PubMed ID: 12803854
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
Idowu OR; Peggins JO; Brewer TG; Kelley C
Drug Metab Dispos; 1995 Jan; 23(1):1-17. PubMed ID: 7720510
[TBL] [Abstract][Full Text] [Related]
47. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
Olesen OV; Linnet K
Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
[TBL] [Abstract][Full Text] [Related]
48. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.
Olesen OV; Linnet K
Pharmacology; 1997 Nov; 55(5):235-43. PubMed ID: 9399333
[TBL] [Abstract][Full Text] [Related]
49. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
50. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
[TBL] [Abstract][Full Text] [Related]
51. Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.
Zhuang XM; Deng JT; Li H; Kong WL; Ruan JX; Xie L
Acta Pharmacol Sin; 2011 Oct; 32(10):1276-84. PubMed ID: 21970838
[TBL] [Abstract][Full Text] [Related]
52. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.
Nielsen LM; Holm NB; Olsen L; Linnet K
Drug Test Anal; 2016 Aug; 8(8):792-800. PubMed ID: 26360322
[TBL] [Abstract][Full Text] [Related]
53. Metabolite identification of the antimalarial naphthoquine using liquid chromatography-tandem high-resolution mass spectrometry in combination with multiple data-mining tools.
Sun Y; Wang S; Ji J; Zhai G; Xing J
Biomed Chromatogr; 2018 Jun; 32(6):e4207. PubMed ID: 29430676
[TBL] [Abstract][Full Text] [Related]
54. Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes.
Fasinu PS; Nanayakkara NPD; Wang YH; Chaurasiya ND; Herath HMB; McChesney JD; Avula B; Khan I; Tekwani BL; Walker LA
Malar J; 2019 Jan; 18(1):30. PubMed ID: 30700282
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs.
Chaurasiya ND; Ganesan S; Nanayakkara NP; Dias LR; Walker LA; Tekwani BL
Bioorg Med Chem Lett; 2012 Feb; 22(4):1701-4. PubMed ID: 22264472
[TBL] [Abstract][Full Text] [Related]
56. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; de Brito CFA; Gil JP; de Sousa TN
J Antimicrob Chemother; 2024 Jun; ():. PubMed ID: 38870082
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
58. Biotransformation of BDE-47 to potentially toxic metabolites is predominantly mediated by human CYP2B6.
Feo ML; Gross MS; McGarrigle BP; Eljarrat E; Barceló D; Aga DS; Olson JR
Environ Health Perspect; 2013 Apr; 121(4):440-6. PubMed ID: 23249762
[TBL] [Abstract][Full Text] [Related]
59. Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers.
Khan W; Wang YH; Chaurasiya ND; Nanayakkara ND; Herath HB; Harrison KA; Dale G; Stanford DA; Dahl EP; McChesney JD; Gul W; ElSohly MA; Khan SI; Fasinu PS; Khan IA; Tekwani BL; Walker LA
Drug Metab Pharmacokinet; 2022 Aug; 45():100463. PubMed ID: 35709685
[TBL] [Abstract][Full Text] [Related]
60. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
